- Open Access
Adrenocortical suppression and recovery after continuous hypnotic infusion: etomidate versus its soft analogue cyclopropyl-methoxycarbonyl metomidate
Critical Care volume 17, Article number: R20 (2013)
Etomidate is no longer administered as a continuous infusion for anesthetic maintenance or sedation, because it results in profound and persistent suppression of adrenocortical steroid synthesis with potentially lethal consequences in critically ill patients. We hypothesized that rapidly metabolized soft analogues of etomidate could be developed that do not produce persistent adrenocortical dysfunction even after prolonged continuous infusion. We hope that such agents might also provide more rapid and predictable anesthetic emergence. We have developed the soft etomidate analogue cyclopropyl-methoxycarbonyl etomidate (CPMM). Upon termination of 120-minute continuous infusions, hypnotic and encephalographic recoveries occur in four minutes. The aims of this study were to assess adrenocortical function during and following 120-minute continuous infusion of CPMM and to compare the results with those obtained using etomidate.
Dexamethasone-suppressed rats were randomized into an etomidate group, CPMM group, or control group. Rats in the etomidate and CPMM groups received 120-minute continuous infusions of etomidate and CPMM, respectively. Rats in the control group received neither hypnotic. In the first study, adrenocortical function during hypnotic infusion was assessed by administering adrenocorticotropic hormone (ACTH) 90 minutes after the start of the hypnotic infusion and measuring plasma corticosterone concentrations at the end of the infusion 30 minutes later. In the second study, adrenocortical recovery following hypnotic infusion was assessed by administering ACTH every 30 minutes after infusion termination and measuring plasma corticosterone concentrations 30 minutes after each ACTH dose.
During hypnotic infusion, ACTH-stimulated serum corticosterone concentrations were significantly lower in the CPMM and etomidate groups than in the control group (100 ± 64 ng/ml and 33 ± 32 ng/ml versus 615 ± 265 ng/ml, respectively). After hypnotic infusion, ACTH-stimulated serum corticosterone concentrations recovered to control values within 30 minutes in the CPMM group but remained suppressed relative to those in the control group for more than 3 hours in the etomidate group.
Both CPMM and etomidate suppress adrenocortical function during continuous infusion. However, recovery occurs significantly more rapidly following infusion of CPMM.
Etomidate is an imidazole-based intravenous sedative-hypnotic (Figure 1). It was developed by Janssen Pharmaceuticals in the 1960s and introduced into clinical practice as an anesthetic induction and maintenance agent a decade later . Since its introduction, widespread concerns regarding its use, particularly in the critically ill, have arisen because it produces profound and persistent adrenocortical suppression by inhibiting 11β-hydroxylase [2–10].
Considering the hypothesis that rapidly metabolized soft analogues of etomidate that would not produce persistent adrenocortical suppression could be designed, our laboratory developed methoxycarbonyl etomidate . Similar to remifentanil and esmolol, methoxycarbonyl etomidate is rapidly metabolized by esterases to a carboxylic acid metabolite. As a hypnotic and inhibitor of adrenocortical steroid synthesis, this metabolite is two to three orders of magnitude less potent than the parent compound . When given as an intravenous bolus to rats, methoxycarbonyl etomidate is an extremely short-acting hypnotic agent that maintains hemodynamic stability and does not produce prolonged adrenocortical suppression .
Subsequent continuous infusion studies demonstrated that the very rapid metabolism of methoxycarbonyl etomidate, along with its relatively low potency, necessitated very high dosing to maintain hypnosis . This led to the accumulation of metabolite, and concentrations in the blood and cerebrospinal fluid reached the millimolar levels sufficient to produce pharmacological effects that persisted for hours. We have now developed a second-generation soft etomidate analogue, cyclopropyl-methoxycarbonyl etomidate (CPMM), which is more potent and longer-lasting than methoxycarbonyl etomidate but still more rapidly metabolized than etomidate . Unlike with methoxycarbonyl etomidate or etomidate, hypnotic and encephalographic recoveries occur in 4 minutes independently of infusion duration . The aims of this study were to assess adrenocortical function during and after 120-minute continuous infusion of CPMM and to compare the results with those obtained by using etomidate.
Materials and methods
All studies were conducted with the approval of the Institutional Animal Care and Use Committee at Massachusetts General Hospital (Boston, MA, USA) and in accordance with its rules and regulations. Adult male Sprague-Dawley rats (250 to 500 g) were purchased from Charles River Laboratories (Wilmington, MA, USA) and housed in the Massachusetts General Hospital Center for Comparative Medicine animal care facility. All intravenous drugs were administered through a femoral venous catheter pre-implanted by the vendor prior to animal delivery to our animal care facility. Each rat was individually caged with controlled temperature (21 ± 2°C) and light-dark cycles (7 a.m. to 7 p.m.) in the Massachusetts General Hospital Center for Comparative Medicine animal care facility, and food and water were provided at libitum.
Etomidate (2 mg/mL in 35% propylene glycol/water) was from Hospira (Lake Forest, IL, USA). CPMM was synthesized (> 97% purity) by Aberjona Laboratories (Beverly, MA, USA) by using our previously described approach  and solubilized at 5 mg/mL in 10% propylene glycol/normal saline. Dexamethasone was purchased from American Regent (Shirley, NY, USA), and adrenocorticotropic hormone (ACTH) was from Sigma-Aldrich (St. Louis, MO, USA).
Hypnotic drug infusion protocol
Our goals were to achieve and maintain approximately equivalent anesthetic depths during 120-minute hypnotic infusions. Therefore, for each hypnotic, we used a continuous infusion protocol that, as we previously determined , achieves the following behavioral endpoints: (a) it maintains the electroencephalographic burst suppression ratio at 80% (in a background of 1% isoflurane) and (b) it administers a steady-state dose that is 1.3 times that required to produce immobility to a standard noxious stimulus (in the absence of isoflurane). The total doses of CPMM and etomidate delivered during 2-hour infusions were 143 and 36 mg/kg, respectively. During hypnotic infusion, the body temperature of each rat was measured with a rectal thermistor and maintained at 37 ± 0.2°C by using a heat lamp. Rats in the control group received dexamethasone but no hypnotic during the hypnotic infusion protocol and were allowed to roam freely in their cages.
Assessment of adrenocortical function during hypnotic drug infusion
Rats were given intravenous dexamethasone (0.2 mg) to suppress corticosterone synthesis elicited by endogenous ACTH and reduce baseline corticosterone concentrations. Rats were then randomly assigned to CPMM, etomidate, or control groups. Two hours after dexamethasone administration, a baseline blood sample was drawn, a second dose of dexamethasone was given, and the hypnotic infusion protocol was begun. Ninety minutes after the protocol began, ACTH (0.25 mg/kg) was given intravenously to stimulate corticosterone production, and a second blood sample was drawn 30 minutes later (that is, at the end of the infusion protocol). Thus, the corticosterone concentration in the second blood sample was a measure of the extent of adrenocortical inhibition during the final 30 minutes of the infusion (Figure 2A).
Assessment of adrenocortical recovery after hypnotic drug infusion
Rats were given intravenous dexamethasone (0.2 mg) and randomly assigned to CPMM, etomidate, or control groups. Two hours after dexamethasone administration, a baseline blood sample was drawn, a second dose of dexamethasone was given, and the hypnotic infusion protocol was begun. After the 120-minute infusion protocol was completed, ACTH (0.25 mg/kg) was given intravenously every 30 minutes for 3 hours to maintain adrenocortical stimulation, and blood samples were drawn 30 minutes after each ACTH dose. The time course of adrenocortical recovery was assessed from the time-dependent corticosterone concentration increase that occurred with repetitive ACTH administration (Figure 2B).
Measurement of serum corticosterone concentrations
Serum corticosterone concentrations in blood samples were determined as previously described  by using an enzyme-linked immunosorbent assay (Diagnostic Systems Laboratories, Webster, TX, USA) and a 96-well plate reader (Molecular Devices, Sunnyvale, CA, USA).
All data are presented as mean ± standard deviation. Statistical analyses were carried out by using Prism version 5.0 for the Macintosh (GraphPad Software, Inc., La Jolla, CA, USA). For multiple comparisons, we performed either a one-way or two-way analysis of variance followed by a Bonferroni post-test. A P value less than 0.05 was considered statistically significant.
Suppression of adrenocortical function during hypnotic drug infusion
Baseline serum corticosterone concentrations prior to the start of the infusion protocol were not significantly different among the three groups and averaged 37 ± 111 ng/mL. After administration of ACTH, serum corticosterone concentrations in the CPMM and etomidate groups were 100 ± 64 ng/mL (n = 6) and 33 ± 32 ng/mL (n = 6), respectively (Figure 3). These values were not significantly different from one another but were significantly lower than that measured in the control group (615 ± 265 ng/mL, n = 6, P < 0.001).
Recovery of adrenocortical function after hypnotic drug infusion
Baseline serum corticosterone concentrations prior to the start of the infusion protocol or administration of ACTH were not significantly different among the three groups and averaged 63 ± 108 ng/mL. With ACTH administration, serum corticosterone concentrations increased over time in all three groups (Figure 4). At every time point of the study, ACTH-stimulated serum corticosterone concentrations in the CPMM and control groups were not significantly different. In contrast, ACTH-stimulated serum corticosterone concentrations in the etomidate group were significantly lower than in either the CPMM or control groups for all time points.
This study shows that, during 120-minute continuous infusions of CPMM and etomidate, ACTH-stimulated serum corticosterone concentrations were significantly reduced relative to the control value. However, after the infusion was completed, ACTH-stimulated serum corticosterone concentrations were not significantly different from control values within 30 minutes in rats that received CPMM, but remained significantly lower than control values for more than 3 hours in rats that received etomidate. We conclude that continuous infusions of CPMM and etomidate cause adrenocortical suppression but that adrenocortical recovery occurs more quickly after infusions of CPMM as compared with etomidate.
Suppression of adrenocortical function is a common side effect of etomidate administration that results from the inhibition of 11β-hydroxylase, an enzyme required for the biosynthesis of cortisol, corticosterone, and aldosterone [4, 16–18]. This potentially deadly side effect has led anesthesiologists and intensivists to abandon its use by continuous infusion for anesthetic maintenance or sedation [3, 19]. Although etomidate continues to be used as an anesthetic induction agent, significant concerns about the impact of even a single bolus dose remain because even this brief exposure produces long-lasting adrenocortical suppression that may be detrimental to the critically ill [6–10, 20–22].
Why is adrenocortical function suppressed for so long after etomidate administration? The adrenocortical inhibitory potency of etomidate is two to three orders of magnitude greater than its hypnotic potency [23–27]. Thus, a typical anesthetic induction dose of etomidate represents a massive overdose with respect to adrenocortical inhibition, and etomidate concentrations in blood fall below those that produce adrenocortical suppression only after the passage of multiple elimination half-lives.
Our goal in creating soft etomidate analogues was to produce agents that may be given as either a bolus (for anesthetic induction) or continuous infusion (for anesthetic maintenance) without producing persistent adrenocortical suppression since they are rapidly eliminated. We hoped that such agents might also allow fast emergence from anesthesia, which might ultimately benefit patients while improving operational efficiencies. Our first soft etomidate analogue, methoxycarbonyl etomidate, achieved these goals when given as a single bolus since hypnotic recovery was rapid and adrenocortical suppression was brief . However, because it was so rapidly metabolized and possessed relatively low hypnotic potency, dosing requirements during continuous infusion were extremely high . As a consequence, metabolite accumulated during infusions and recovery times were highly dependent upon the duration of hypnotic infusion (that is, recovery was context-dependent).
With the goals of slowing methoxycarbonyl etomidate's exceptionally fast rate of metabolism and reducing the extent of metabolite accumulation during infusions, we modified the drug's chemical structure by adding a cyclopropyl group directly adjacent to the metabolically labile ester moiety (to sterically hinder enzymatic attack) and shortening the spacer between that ester and the etomidate core (Figure 1). This structural change increased both the duration of hypnotic action and hypnotic potency by approximately eightfold . As a result, dosing requirements for continuous CPMM infusions are one to two orders of magnitude lower than those for methoxycarbonyl etomidate infusions, and neither hypnotic nor encephalographic recoveries are delayed by the accumulation of metabolite [14, 15].
We believe that the introduction of CPMM into clinical practice could have a significant impact on patient care by allowing anesthesia to be maintained, even in older or critically ill patients, without producing significant cardiovascular depression or persistent adrenocortical dysfunction. It may also allow more rapid and predictable anesthetic emergence than is possible with currently available agents.
There are several limitations of our study. First is the use of a rat model to study adrenocortical recovery after hypnotic infusion. Rats often metabolize ester-containing drugs (including etomidate) faster than humans [28, 29]. Therefore, adrenocortical recovery following infusion of CPMM and etomidate may be somewhat slower in humans than we observed in rats. Second, rats use corticosterone, rather than cortisol, as the primary stress steroid. Thus, we are studying a different steroid. However, because the biosynthesis of both steroids requires 11β-hydroxylase, suppression of corticosterone synthesis in rats is expected to be a relevant measure of adrenocortical function in the setting of etomidate or CPMM administration. Finally, we used a protocol for assessing the time course of adrenocortical recovery in which ACTH is administered multiple times, introducing the potential for adrenal fatigue toward the end of the study. Such fatigue would be greater for rats in the control and CPMM groups that are most actively producing steroids but would not alter our conclusions.
The development of soft etomidate analogues follows a trend in drug development toward agents that are ultra-short-acting and is in response to the need in the operating room and intensive care unit for more precise temporal control of drug effects . Esmolol and remifentanil are commonly used examples of soft drugs that serve this need and use the same labile ester strategy employed in our etomidate analogues . The esterase-metabolized soft calcium channel blocker clevidipine was recently introduced into clinical practice for the acute treatment of hypertension , and the esterase-metabolized soft midazolam analogue remimazolam is currently undergoing clinical trials . By offering rapid emergence from anesthesia and prompt return of adrenocortical function, CPMM may join the growing list of soft drugs available for clinical use.
Adrenocortical function was suppressed during 120-minute continuous infusions of CPMM and etomidate in a rat model. However, after infusion termination, adrenocortical recovery occurred in less than 30 minutes with CPMM but persisted for more than 3 hours with etomidate.
Cyclopropyl-methoxycarbonyl etomidate (CPMM) is a rapidly metabolized analogue of etomidate.
CPMM and etomidate suppress adrenocortical steroid synthesis during 120-minute continuous infusions.
Upon termination of 120-minute continuous infusions, adrenocortical recovery occurs faster with CPMM (< 30 minutes) than with etomidate (> 3 hours).
CPMM may be a viable alternative to other sedative hypnotics (for example, propofol, etomidate, and inhaled agents) in which intraoperative hemodynamic stability and rapid anesthetic recovery are desirable, and adrenocortical suppression persisting for little more than the duration of hypnotic administration is acceptable.
Godefroi EF, Janssen PA, Vandereycken CA, Vanheertum AH, Niemegeers CJ: Dl-1-(1-arylalkyl)imidazole-5-carboxylate esters. A novel type of hypnotic agent. J Med Chem 1965, 8: 220-223. 10.1021/jm00326a017
Ledingham IM, Watt I: Influence of sedation on mortality in critically ill multiple trauma patients. Lancet 1983, 1: 1270.
Watt I, Ledingham IM: Mortality amongst multiple trauma patients admitted to an intensive therapy unit. Anaesthesia 1984, 39: 973-981. 10.1111/j.1365-2044.1984.tb08885.x
Fry DE, Griffiths H: The inhibition by etomidate of the 11 beta-hydroxylation of cortisol. Clin Endocrinol (Oxf) 1984, 20: 625-629. 10.1111/j.1365-2265.1984.tb00112.x
den Brinker M, Joosten KF, Liem O, de Jong FH, Hop WC, Hazelzet JA, van Dijk M, Hokken-Koelega AC: Adrenal insufficiency in meningococcal sepsis: bioavailable cortisol levels and impact of interleukin-6 levels and intubation with etomidate on adrenal function and mortality. J Clin Endocrinol Metab 2005, 90: 5110-5117. 10.1210/jc.2005-1107
Lipiner-Friedman D, Sprung CL, Laterre PF, Weiss Y, Goodman SV, Vogeser M, Briegel J, Keh D, Singer M, Moreno R, Bellissant E, Annane D: Adrenal function in sepsis: the retrospective Corticus cohort study. Crit Care Med 2007, 35: 1012-1018. 10.1097/01.CCM.0000259465.92018.6E
Hildreth AN, Mejia VA, Maxwell RA, Smith PW, Dart BW, Barker DE: Adrenal suppression following a single dose of etomidate for rapid sequence induction: a prospective randomized study. J Trauma 2008, 65: 573-579. 10.1097/TA.0b013e31818255e8
Cuthbertson BH, Sprung CL, Annane D, Chevret S, Garfield M, Goodman S, Laterre PF, Vincent JL, Freivogel K, Reinhart K, Singer M, Payen D, Weiss YG: The effects of etomidate on adrenal responsiveness and mortality in patients with septic shock. Intensive Care Med 2009, 35: 1868-1876. 10.1007/s00134-009-1603-4
Chan CM, Mitchell AL, Shorr AF: Etomidate is associated with mortality and adrenal insufficiency in sepsis: a meta-analysis*. Crit Care Med 2012, 40: 2945-2953. 10.1097/CCM.0b013e31825fec26
Asehnoune K, Mahe PJ, Seguin P, Jaber S, Jung B, Guitton C, Chatel-Josse N, Subileau A, Tellier AC, Masson F, Renard B, Malledant Y, Lejus C, Volteau C, Sebille V, Roquilly A: Etomidate increases susceptibility to pneumonia in trauma patients. Intensive Care Med 2012, 38: 1673-1682. 10.1007/s00134-012-2619-8
Cotten JF, Husain SS, Forman SA, Miller KW, Kelly EW, Nguyen HH, Raines DE: Methoxycarbonyl-etomidate: a novel rapidly metabolized and ultra-short-acting etomidate analogue that does not produce prolonged adrenocortical suppression. Anesthesiology 2009, 111: 240-249. 10.1097/ALN.0b013e3181ae63d1
Ge RL, Pejo E, Haburcak M, Husain SS, Forman SA, Raines DE: Pharmacological studies of methoxycarbonyl etomidate's carboxylic acid metabolite. Anesth Analg 2012, 115: 305-308. 10.1213/ANE.0b013e318239c6ca
Pejo E, Ge R, Banacos N, Cotten JF, Husain SS, Raines DE: Electroencephalographic recovery, hypnotic emergence, and the effects of metabolite following continuous infusions of a rapidly metabolized eomidate analog in rats. Anesthesiology 2012, 116: 1057-1065. 10.1097/ALN.0b013e3182515403
Husain SS, Pejo E, Ge R, Raines DE: Modifying methoxycarbonyl etomidate inter-ester spacer optimizes in vitro metabolic stability and in vivo hypnotic potency and duration of action. Anesthesiology 2012, 117: 1027-1036. 10.1097/ALN.0b013e31826d3bef
Ge R, Pejo E, Husain SS, Cotten JF, Raines DE: Electroencephalographic and hypnotic recoveries following brief and prolonged infusions of etomidate and optimized soft etomidate analogs. Anesthesiology 2012, 117: 1037-1043. 10.1097/ALN.0b013e31826d3de2
de Jong FH, Mallios C, Jansen C, Scheck PA, Lamberts SW: Etomidate suppresses adrenocortical function by inhibition of 11 beta-hydroxylation. J Clin Endocrinol Metab 1984, 59: 1143-1147. 10.1210/jcem-59-6-1143
Fragen RJ, Shanks CA, Molteni A, Avram MJ: Effects of etomidate on hormonal responses to surgical stress. Anesthesiology 1984, 61: 652-656. 10.1097/00000542-198412000-00004
Wagner RL, White PF: Etomidate inhibits adrenocortical function in surgical patients. Anesthesiology 1984, 61: 647-651. 10.1097/00000542-198412000-00003
Fellows IW, Bastow MD, Byrne AJ, Allison SP: Adrenocortical suppression in multiply injured patients: a complication of etomidate treatment. Br Med J (Clin Res Ed) 1983, 287: 1835-1837. 10.1136/bmj.287.6408.1835
Absalom A, Pledger D, Kong A: Adrenocortical function in critically ill patients 24 h after a single dose of etomidate. Anaesthesia 1999, 54: 861-867. 10.1046/j.1365-2044.1999.01003.x
den Brinker M, Hokken-Koelega AC, Hazelzet JA, de Jong FH, Hop WC, Joosten KF: One single dose of etomidate negatively influences adrenocortical performance for at least 24 h in children with meningococcal sepsis. Intensive Care Med 2008, 34: 163-168. 10.1007/s00134-007-0836-3
Kulstad EB, Kalimullah EA, Tekwani KL, Courtney DM: Etomidate as an induction agent in septic patients: red flags or false alarms? West J Emerg Med 2010, 11: 161-172.
Tomlin SL, Jenkins A, Lieb WR, Franks NP: Stereoselective effects of etomidate optical isomers on gamma-aminobutyric acid type A receptors and animals. Anesthesiology 1998, 88: 708-717. 10.1097/00000542-199803000-00022
Husain SS, Ziebell MR, Ruesch D, Hong F, Arevalo E, Kosterlitz JA, Olsen RW, Forman SA, Cohen JB, Miller KW: 2-(3-Methyl-3H-diaziren-3-yl)ethyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate: a derivative of the stereoselective general anesthetic etomidate for photolabeling ligand-gated ion channels. J Med Chem 2003, 46: 1257-1265. 10.1021/jm020465v
Roumen L, Sanders MP, Pieterse K, Hilbers PA, Plate R, Custers E, de Gooyer M, Smits JF, Beugels I, Emmen J, Ottenheijm HCJ, Leysen D, Hermans JJR: Construction of 3D models of the CYP11B family as a tool to predict ligand binding characteristics. J Comput Aided Mol Des 2007, 21: 455-471. 10.1007/s10822-007-9128-9
Cotten JF, Forman SA, Laha JK, Cuny GD, Husain SS, Miller KW, Nguyen HH, Kelly EW, Stewart D, Liu A, Raines DE: Carboetomidate: a pyrrole analog of etomidate designed not to suppress adrenocortical function. Anesthesiology 2010, 112: 637-644. 10.1097/ALN.0b013e3181cf40ed
Forman SA: Clinical and molecular pharmacology of etomidate. Anesthesiology 2011, 114: 695-707. 10.1097/ALN.0b013e3181ff72b5
Calvo R, Carlos R, Erill S: Etomidate and plasma esterase activity in man and experimental animals. Pharmacology 1979, 18: 294-298. 10.1159/000137268
Quon CY, Mai K, Patil G: Species differences in the stereoselective hydrolysis of esmolol by blood esterases. Drug Metab Dispos 1988, 16: 425-428.
Egan TD: Is anesthesiology going soft?: trends in fragile pharmacology. Anesthesiology 2009, 111: 229-230. 10.1097/ALN.0b013e3181ae8460
Bodor N, Buchwald P: Soft drug design: general principles and recent applications. Med Res Rev 2000, 20: 58-101. 10.1002/(SICI)1098-1128(200001)20:1<58::AID-MED3>3.0.CO;2-X
Sarafidis PA, Georgianos PI, Malindretos P, Liakopoulos V: Pharmacological management of hypertensive emergencies and urgencies: focus on newer agents. Expert Opin Investig Drugs 2012, 21: 1089-1106. 10.1517/13543784.2012.693477
Antonik LJ, Goldwater DR, Kilpatrick GJ, Tilbrook GS, Borkett KM: A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part I. Safety, efficacy, and basic pharmacokinetics. Anesth Analg 2012, 115: 274-283. 10.1213/ANE.0b013e31823f0c28
This work was funded by grants R01-GM087316 and R21-DA029253 from the National Institutes of Health (Bethesda, MD, USA) and by the Department of Anesthesia, Critical Care, and Pain Medicine of Massachusetts General Hospital (Boston, MA, USA).
Massachusetts General Hospital has submitted patent applications for soft etomidate analogues. Two authors (JFC and DER) and their respective laboratories, departments, and institutions could receive compensation related to the development or sale of the technology presented in this report. DER is a consultant for and holds an equity interest in Annovation BioPharma Inc. (Cambridge, MA, USA), which has licensed this technology for development. RG and EP declare that they have no competing interests.
RG participated in the design of the study, carried out the data acquisition and analysis, and participated in drafting the manuscript. EP assisted with study design, data acquisition, and analysis and participated in drafting the manuscript. JFC developed and implemented the computer software to administer hypnotics and assisted with study design and drafting the manuscript. DER conceived and designed the study, carried out the coordination, performed the statistical analyses, and drafted the manuscript. All authors read and approved the final manuscript.
About this article
Cite this article
Ge, R., Pejo, E., Cotten, J.F. et al. Adrenocortical suppression and recovery after continuous hypnotic infusion: etomidate versus its soft analogue cyclopropyl-methoxycarbonyl metomidate. Crit Care 17, R20 (2013). https://doi.org/10.1186/cc12494
- Corticosterone Concentration